CRISM Therapeutics (LON:CRTX) Issues Quarterly Earnings Results

CRISM Therapeutics (LON:CRTX) released its earnings results on Friday. The company reported GBX (0.05) earnings per share (EPS) for the quarter, Digital Look Earnings reports.

CRISM Therapeutics Trading Down 5.0%

Shares of CRISM Therapeutics stock opened at GBX 9.50 on Friday. CRISM Therapeutics has a 1 year low of GBX 8 and a 1 year high of GBX 23. The company’s fifty day simple moving average is GBX 11.44 and its 200-day simple moving average is GBX 11.65. The company has a market cap of £5.15 million, a price-to-earnings ratio of -2.16 and a beta of 0.58.

About CRISM Therapeutics

CRISM Therapeutics Corporation is clinical stage company, having developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM’s lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin.